Faecal calprotectin in the assessment of Crohn's disease activity
- PMID: 15879440
- DOI: 10.1093/qjmed/hci069
Faecal calprotectin in the assessment of Crohn's disease activity
Abstract
Background: Clinical and laboratory assessment of activity in Crohn's disease (CD) correlate poorly with endoscopic findings. Calprotectin is a calcium-binding protein abundant in neutrophil cytosol, and extremely stable in faeces. Faecal calprotectin (FC) is an excellent surrogate marker of neutrophil influx into the bowel lumen.
Aim: To assess whether FC concentration from a spot stool sample reliably detects active inflammation in patients with CD.
Design: Cross-sectional comparative study.
Methods: Subjects had a previously confirmed diagnosis of CD and were suspected on clinical grounds to be in the midst of a relapse. Thirty-five entered the study; they underwent radiolabelled white cell scanning (WCS) and had a stool sample collected for calprotectin measurement on the same day. A Crohn's disease activity index (CDAI) was also calculated for each. The WCS scans were scored at six standard sites to give a mean total, 'extent', 'severity' and 'combined extent and severity' scores.
Results: FC was significantly and positively correlated with mean total (r = 0.73, p < 0.001), 'extent' (r = 0.71, p < 0.001), 'severity' (r = 0.64, p < 0.001) and combined 'extent and severity' WCS scores (r = 0.71, p < 0.001). A cut-off of faecal calprotectin > 100 microg/g gave a sensitivity of 80%, specificity of 67%, positive predictive value of 87% and a negative predictive value of 64% in identifying those with and without any inflammation on WCS. There was, however, no significant correlation between CDAI and mean total WCS score (r = 0.21, p = 0.24), nor between CDAI and FC (r = 0.33, p = 0.06).
Discussion: While the CDAI does not accurately reflect inflammatory activity in CD, a one-off FC reliably detects the presence or absence of intestinal inflammation in adult patients with CD, compared to WCS.
Similar articles
-
Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.Am J Gastroenterol. 2010 Jan;105(1):162-9. doi: 10.1038/ajg.2009.545. Epub 2009 Sep 15. Am J Gastroenterol. 2010. PMID: 19755969
-
Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.Dig Liver Dis. 2008 Jul;40(7):547-53. doi: 10.1016/j.dld.2008.01.017. Epub 2008 Mar 20. Dig Liver Dis. 2008. PMID: 18358796
-
Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.Aliment Pharmacol Ther. 2008 Nov 15;28(10):1221-9. doi: 10.1111/j.1365-2036.2008.03835.x. Epub 2008 Aug 26. Aliment Pharmacol Ther. 2008. PMID: 18752630
-
Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.Dig Liver Dis. 2009 Jan;41(1):56-66. doi: 10.1016/j.dld.2008.05.008. Epub 2008 Jul 3. Dig Liver Dis. 2009. PMID: 18602356 Review.
-
[Measurement of calprotectin in faeces].Tidsskr Nor Laegeforen. 2009 Apr 16;129(8):743-5. doi: 10.4045/tidsskr.08.0010. Tidsskr Nor Laegeforen. 2009. PMID: 19373299 Review. Norwegian.
Cited by
-
Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease?: a systematic review.Intest Res. 2019 Apr;17(2):160-170. doi: 10.5217/ir.2018.00114. Epub 2019 Feb 7. Intest Res. 2019. PMID: 30704158 Free PMC article.
-
Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease.Microbiome. 2021 Aug 23;9(1):176. doi: 10.1186/s40168-021-01135-5. Microbiome. 2021. PMID: 34425887 Free PMC article.
-
Utility of faecal calprotectin analysis in adult inflammatory bowel disease.World J Gastroenterol. 2012 Dec 14;18(46):6782-9. doi: 10.3748/wjg.v18.i46.6782. World J Gastroenterol. 2012. PMID: 23239916 Free PMC article.
-
Bootstrapping random forest and CHAID for prediction of white spot disease among shrimp farmers.Sci Rep. 2022 Dec 3;12(1):20876. doi: 10.1038/s41598-022-25109-1. Sci Rep. 2022. PMID: 36463244 Free PMC article.
-
RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.AIDS Res Hum Retroviruses. 2012 Nov;28(11):1412-21. doi: 10.1089/aid.2012.0262. Epub 2012 Oct 9. AIDS Res Hum Retroviruses. 2012. PMID: 22943559 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical